Pharma BD Deal Intelligence
A $10.9B all-cash acquisition giving AbbVie the anti-IL-13 antibody zumilokibart (APG777) to deepen its immunology pipeline beyond Humira/Rinvoq successors. Phase 2 data showed roughly two-thirds of atopic dermatitis patients achieving significant skin clearance at 16 weeks on quarterly or twice-yearly dosing, though the asset still needs to clear Phase 3 before AbbVie sees a return on the year's second-largest biotech deal.
Post-Humira immunology backfill with a Phase 3 IL-13 antibody
Full analysis, sources & comparables →AbbVie to acquire Apogee Therapeutics for ~$10.9 billion at $135.11 per share in cash; lead asset zumilokibart (APG777), an anti-IL-13 mAb for atopic…
AbbVie Form 8-K announcing definitive agreement to acquire Apogee Therapeutics.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion in an all-cash transaction at $135.11 per share, deepening AbbVie's immunology portfolio. Apogee's lead candidate zumilokibart (APG777) is a subcutaneous, half-life-extended anti-IL-13 monoclonal antibody in development for atopic dermatitis and asthma, with Phase 2 data showing ~two-thirds of treated patients achieving significant skin clearance at 16 weeks on quarterly or twice-yearly dosing. It is the year's second-largest biotech acquisition.
On June 22, 2026 AbbVie agreed to acquire Apogee Therapeutics for $135.11/share in cash (~$10.9B equity value), adding a pipeline of half-life-extended biologics across inflammatory and immunological diseases. Lead asset zumilokibart (APG777) is a subcutaneous, half-life extended anti-IL-13 monoclonal antibody in late-stage development for atopic dermatitis, with Phase 2 data showing meaningful skin-clearance and itch improvement and supporting Q3M/Q6M maintenance dosing. The portfolio also spans asthma/COPD and other I&I targets. Close expected Q3 2026, pending Apogee shareholder and regulatory approvals.
AbbVie agrees to acquire Apogee for $135.11/share cash (~$10.9B), gaining IL-13 lead zumilokibart (APG777) plus a half-life-extended I&I pipeline. Close expected Q3 2026.
AbbVie pays a full ~$10.9B for a de-risked Phase 3 IL-13 asset to backfill post-Humira immunology; execution risk is competitive positioning vs. dupilumab/lebrikizumab, not stage risk.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Apogee Therapeutics, Inc. (this deal) | 2026 | $10.9B | 72 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
| AbbVie Inc. / MedinCell S.A. | 2024 | $1.9B | 61 |
← Browse all deals · How we score deals
More: 2026 deals · AbbVie Inc. deals · Immunology deals